SCHEMBL6369583

SCHEMBL6369583

CCN1CCc2cc(OC)c(OC)cc2C1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.69
L3MBTL1 Q9Y468 1/20 0.63
KDM4E B2RXH2 5/20 0.61
MAPT P10636 2/20 0.61
GAA P10253 1/20 0.61
RAB9A P51151 1/20 0.61
MAOA P21397 2/20 0.61
MAOB P27338 2/20 0.61
SLC6A4 P31645 1/20 0.61
KMT2A Q03164 1/20 0.60
ALDH1A1 P00352 2/20 0.57
TSHR P16473 2/20 0.57
ABCC1 P33527 2/20 0.57
ABCG2 Q9UNQ0 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
ALOX15 P16050 1/20 0.57
CASP1 P29466 1/20 0.57
CASP7 P55210 1/20 0.57
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25947932 0.90 ABCB1 (0.58) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL6370878 0.90 ABCB1 (0.58) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL22864687 0.89 ABCB1 (0.57) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL3506070 0.89 CA2 (0.67) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL25946919 0.88 ABCB1 (0.56) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL913887 0.87 ABCB1 (0.67) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL10383656 0.87 ABCB1 (0.56) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL25568846 0.86 ABCB1 (0.80) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL14163737 0.84 ABCB1 (0.63) ABCB1L3MBTL1KDM4EMAPTGAA
SCHEMBL24729539 0.83 ABCB1 (0.54) ABCB1L3MBTL1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204002-B1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS INTERNATIONAL SOC FOR DRUG DEVELOPMENT S R L (IT) 2021-05-19 EP disclosed
WO-2019070973-A1 CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS GLADIUS PHARMACEUTICALS CORPORATION (CA) 2019-04-11 WO disclosed
WO-2019070973-A1 CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS GLADIUS PHARMACEUTICALS CORPORATION (CA) 2019-04-11 WO disclosed
US-20190100534-A1 Cephem Compounds with Latent Reactive Groups GLADIUS PHARMACEUTICALS INC (CA) 2019-04-04 US disclosed
US-20190100534-A1 Cephem Compounds with Latent Reactive Groups GLADIUS PHARMACEUTICALS INC (CA) 2019-04-04 US disclosed
US-9119822-B2 Use of PDE7 inhibitors for the treatment of movement disorders OMEROS CORPORATION (US) 2015-09-01 US disclosed
EP-2518074-B1 Phosphoinositide 3-kinase inhibitor compounds and methods of use HOFFMANN LA ROCHE (CH) 2015-07-22 EP disclosed
WO-2015050212-A1 T-TYPE CALCIUM CHANNEL BLOCKER 日産化学工業株式会社 2015-04-09 WO disclosed
US-8906913-B2 Azabicyclohexanes PANACEA BIOTEC LIMITED (IN) 2014-12-09 US disclosed
EP-2445887-B1 NOVEL AZABICYCLOHEXANES PANACEA BIOTEC LTD (IN) 2014-11-05 EP disclosed
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-12-25 US disclosed
US-20080279821-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-11-13 US disclosed
US-20080269245-A1 Dioxanes and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2008-10-30 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
US-7244853-B2 Dioxanes and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-07-17 US disclosed
US-20040072849-A1 Dioxanes and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-04-15 US disclosed
US-4758568-A Quinoline therapeutic agents PFIZER INC. (US) 1988-07-19 US disclosed
US-4686228-A Quinoline therapeutic agents PFIZER INC. (US) 1987-08-11 US disclosed
US-4656174-A HYPOTENSIVE AGENTS PFIZER INC. (US) 1987-04-07 US disclosed
EP-0100200-A1 2-Substituted 4-amino-6,7-dimethoxyquinolines Pfizer Limited (GB) 1984-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080279821-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, CTSC, SPINT2 ABCB1 165/4885L3MBTL1 3974/4885KDM4E 1120/4885
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 ABCB1 4043/4885L3MBTL1 1291/4885KDM4E 123/4885
US-20040072849-A1 Dioxanes and uses thereof UTS2R, HDAC5, AMDHD2 ABCB1 2194/4885L3MBTL1 3681/4885KDM4E 164/4885
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS PREP, DNPEP, CTSC ABCB1 267/4885L3MBTL1 3394/4885KDM4E 1403/4885
US-20080269245-A1 Dioxanes and uses thereof UTS2R, MAN2B2, AMDHD2 ABCB1 2134/4885L3MBTL1 3510/4885KDM4E 130/4885
US-20190100534-A1 Cephem Compounds with Latent Reactive Groups PGLS, GNE, COMT ABCB1 971/4885L3MBTL1 612/4885KDM4E 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.